Comparison of SCS and PMR in Patients With Refractory Angina Pectoris
Launched by MEDTRONIC · Sep 9, 2005
Trial Information
Current as of June 02, 2025
Terminated
Keywords
ClinConnect Summary
The purpose of this open, parallel, single-center prospective, randomised controlled trial is to compare two treatments: Spinal Cord Stimulation (SCS) and Percutaneous Myocardial Laser Revascularisation (PMR) and assess their use and longer term effect in patients with Refractory Angina Pectoris.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient limiting angina (CCS III or IV) despite maximally tolerated medical therapy
- • Documented coronary artery disease (within the last 9 months prior baseline), which is unsuitable for conventional revascularisation techniques
- • Patient has documented reversible ischemia on nuclear scan (Tc-99 sestamibi)
- • Patient is limited in daily activities, primarily exercice capability, by their angina pain
- • Age 18 or older
- • Patient must understand the therapy and give informed consent
- • Patient must be available for appropriate follow-up times for length of Study
- • Non pregnant woman
- Exclusion criteria:
- • Not candidate for surgical implantation of SCS and/or not for PMR and/or unable to use SCS device appropriately for treatment
- • Patient who has had one or more major cardiac events within 2 months
- • Patient with myocardial wall thickness\< 8 mm in the ischaemic area to be treated as verified by echocardiography
- • Patient with extensive peripheral vascular disease that precludes vascular access required for PMR
- • Patient on intravenous therapy to control their symptoms
- • Patient who is unlikely to survive for more than 12 months due to non cardiac condition e.g.malignancy
- • patient who has other diseases that are considered of greater clinical significance than the angina pectoris that would impact the ability of the clinician to adequately assess the incremental effects of the trial treatment
- • Patient with ejection fraction of less than 30 % as verified by echocardiography
- • Patient with cause of angina other than coronary artery disease (e.g. syndrome "X" patient)
- • Patient who are unable to perform treadmill exercice test per protocol
- • Patient who was previously enrolled in this study, or is currently in another clinical study, which will interfere with this protocol
- • Patient who has has SCS , a TMLR or PMR procedure in the past
- • Patient with an implanted pacemaker or defibrillator
- • Patient who has medical conditions which may require Magnetic resonance Imaging (MRI)
- • Patient with history of dementia or other persisting mental disorders significantly interfering with ability to cooperate or comply with the requirements of the study or comprehend informed consent
- • Patient with history of Alcohol og Drug abuse
About Medtronic
Medtronic is a global leader in medical technology, dedicated to transforming patient care through innovative solutions and therapies. With a rich history of pioneering advancements in cardiovascular, diabetes, neurological, and orthopedic care, Medtronic is committed to improving health outcomes and enhancing the quality of life for patients worldwide. The company actively sponsors clinical trials to evaluate the safety and efficacy of its products, ensuring that rigorous scientific standards are met. Through collaboration with healthcare professionals and institutions, Medtronic seeks to drive clinical research that supports evidence-based practices and fosters advancements in medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Papworth Everard, Cambridge, United Kingdom
Patients applied
Trial Officials
Peter Schofield, MD
Principal Investigator
Papworth Hospital, NHS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials